Stephen is General Partner at IndieBio New York. He oversees relationship building between founders, investors, mentors, and partners.
Stephen was one of the founding scientists at Vertex Pharmaceuticals, working on many drug discovery programs, resulting in the FDA approval of Agenerase & Lexiva. He went on to co-founded Abpro Therapeutics, employing synthetic biology and immunology to accelerate antibody discovery and development. Recruited as CEO of SynbiCITE, the Innovation and Knowledge Center for Synthetic Biology in the UK, he oversaw a dramatic growth in the synthetic biology innovation ecosystem with a record number of startups and fundraising in this sector. At the same time, Stephen co-founded Bio-start, the UK’s first Life Science accelerator.
Stephen has co-authored over 30 peer-reviewed scientific publications, including Nature and Cell, and has several patents issued. He has been featured in Huffington Post, Upstart, BioScience, and is a regular conference speaker and government advisor on Life Science innovation and entrepreneurship.
Stephen has a Ph.D. in Molecular Biology and was recently awarded Royal Society Entrepreneur in Residence at Imperial College London. He is a Member of the Royal Society’s Industrial Fellows College and Fellow of the Royal Society of Biology.
Innovation is the only way to win.Steve Jobs